Bambusa Therapeutics Files S-1 Registration Statement for U.S. IPO
Bambusa Therapeutics, Inc. (SEC file no. 0002044950) filed an S-1 registration statement with the U.S. Securities and Exchange Commission on October 9, 2026, initiating its IPO process on Nasdaq or NYSE. At 56 MB, it is the largest biotech S-1 filing of the day.
51CFO view：CFO must lead ASC 606 revenue policy design for clinical-stage collaborations, ASC 730 R&D expense/capitalization judgments, and ASC 718 equity award valuation modeling — all while establishing PCAOB-compliant financial systems and audit-ready documentation trails.
Bambusa Therapeutics, Inc. (SEC file no. 0002044950) filed an S-1 registration statement with the U.S. Securities and Exchange Commission on October 9, 2026, initiating its IPO process on Nasdaq or NYSE. At 56 MB, it is the largest biotech S-1 filing of the day.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →